Melanoma Associated Antigen (PNL2) Antibody (PNL2), Novus Biologicals™

Melanoma Associated Antigen (PNL2)

0.2mg/mL

Immunohistochemistry (Paraffin), SDS-Page, Immunofluorescence

Unconjugated

Mouse

Human, Mouse, Canine

Melanocyte antigen

Primary

Store at 4C.

PNL2

Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, SDS-Page, Immunofluorescence 0.5 - 1.0 ug/ml

Monoclonal

Purified

RUO

10mM PBS and 0.05% BSA with 0.05% Sodium Azide

IgG1

Protein A or G purified

Anti-PNL2 is a novel monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope id not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angio-myolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF.